Latest Us Growth News

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Singular Health boosted its US presence by deploying 500 additional 3DICOM MD® licenses to Provider Network Solutions, securing FDA 510(k) clearance for its cloud platform, and launching education pilots with Miami-Dade schools and Florida International University.

Gale Pacific reported a $1.3 million operating cash outflow in Q3 FY26 amid Middle East geopolitical tensions but strengthened its net cash position by $18 million year-on-year. The company is executing a revised strategy focused on expanding its US commercial footprint and diversifying manufacturing beyond China.

Decidr AI Industries Ltd (ASX: DAI) reported a doubling of its annualised revenue run rate to A$8.06 million as of March 2026, alongside the launch of its Decidr Agentic Graph platform and significant expansion of its partner ecosystem.

Airtasker Limited posted robust 3Q26 results highlighted by strong Australian marketplace momentum and explosive growth in the UK and US. The company reaffirmed its FY26 guidance, underpinned by strategic media partnerships and a solid cash position.

Zip Co reported a 41.5% jump in third quarter cash EBTDA to $65.1 million, driven by accelerated US transaction volume growth of 43.1% and steady credit losses. The company upgraded its FY26 cash EBTDA guidance to at least $260 million, highlighting robust profitability and expanding customer engagement.

ImpediMed Limited has appointed Erik Anderson as its new CEO and Managing Director, effective 7 April 2026, aiming to boost commercial execution and revenue growth in the US market. Dr Parmjot Bains will remain as an advisor until 30 June 2026 to ensure a smooth leadership transition.

Cyclopharm Limited is rapidly expanding its Technegas® lung imaging technology across the US, securing new contracts and advancing clinical guideline recognition that could boost adoption.

Galilee Energy has appointed a US Advisory Board to drive its Gulf Coast oil and gas expansion, targeting low-risk brownfield assets. The company’s maiden Zydeco-1 well in Louisiana is set to spud in Q2 2026, marking a key milestone in its US growth strategy.

Cyclopharm has secured a multi-site agreement with Northwestern Medicine, marking a major expansion into Chicago’s healthcare market and reinforcing its US growth strategy.

Cyclopharm has secured a significant multi-site agreement with the University of Pennsylvania Health System, marking a major step in its US expansion with installations across 11 clinical locations.

Bubs Australia has delivered a robust first half for FY26, powered by a 48% revenue surge in the US, prompting an upgrade to its full-year earnings guidance.